Resverlogix to Host Epigenetics Focused Symposium at The ERA-EDTA Congress in Madrid, Spain
Calgary, Alberta (ots/PRNewswire) - The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and apabetalone in addressing the significant unmet medical need in chronic kidney disease and cardiovascular disease. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced ...